Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes - Scorecard - MDSpire
Advertisement
Cytomegalovirus DNAemia in Hospitalized Adults With SARS-CoV-2 Infection Requiring Supplemental Oxygen: Virologic and Clinical Characteristics and Association With Outcomes
Clinical Scorecard: Cytomegalovirus DNA Presence in Hospitalized Adults with SARS-CoV-2 Infection Requiring Oxygen Support: Clinical Characteristics, Virologic Insights, and Outcome Associations
At a Glance
Category
Detail
Condition
Cytomegalovirus (CMV) reactivation in hospitalized adults with COVID-19 requiring oxygen support
Key Mechanisms
SARS-CoV-2 infection induces immunosuppression (lymphopenia, cytokine dysregulation) leading to CMV reactivation; CMV viremia modulates immune response and may cause organ injury
Target Population
Adults hospitalized with COVID-19 requiring supplemental oxygen, noninvasive ventilation, or mechanical ventilation (NIAID OS 5–7), CMV-seropositive
Care Setting
Hospital inpatient setting during COVID-19 treatment
Key Highlights
CMV DNAemia occurred in 11% of CMV-seropositive hospitalized COVID-19 patients by day 28, increasing with severity of respiratory support (OS 5: 6.3%, OS 6: 16.4%, OS 7: 24.7%).
Risk factors for CMV DNAemia include older age, male sex, higher baseline disease severity, lymphopenia, and systemic corticosteroid use; remdesivir and baricitinib did not affect CMV risk.
CMV DNAemia is independently associated with delayed clinical recovery, higher SARS-CoV-2 viral load, and increased mortality.
Guideline-Based Recommendations
Diagnosis
Assess CMV serostatus in hospitalized COVID-19 patients requiring oxygen support.
Perform quantitative plasma CMV PCR longitudinally to detect CMV DNAemia, with detection threshold ≥31.2 IU/mL and quantitation threshold ≥50 IU/mL.
Management
Monitor patients with identified CMV DNAemia closely for delayed recovery and increased disease severity.
Consider CMV DNAemia as a factor in clinical decision-making, especially in older patients, males, those with lymphopenia, or receiving corticosteroids.
Monitoring & Follow-up
Longitudinal CMV viral load monitoring at baseline and days 3, 5, 8, 11, 15, and 29 to evaluate viral kinetics and correlate with clinical outcomes.
Monitor SARS-CoV-2 viral load and clinical status concurrently to assess disease progression.
Risks
CMV DNAemia is associated with increased risk of delayed recovery and mortality in hospitalized COVID-19 patients.
Systemic corticosteroid use may increase risk of CMV reactivation.
Patient & Prescribing Data
Hospitalized adults with COVID-19 requiring oxygen support who are CMV-seropositive
Use of remdesivir and baricitinib did not influence the risk of CMV DNAemia; systemic corticosteroids were associated with increased CMV reactivation risk.
Clinical Best Practices
Screen for CMV serostatus in hospitalized COVID-19 patients requiring oxygen support to identify those at risk for reactivation.
Implement longitudinal CMV PCR monitoring in CMV-seropositive patients to detect early CMV DNAemia.
Recognize CMV DNAemia as a marker for worse clinical outcomes and consider its presence when evaluating patient prognosis.
Be cautious with systemic corticosteroid use given its association with increased CMV reactivation risk.
Integrate CMV viral load data with SARS-CoV-2 viral load and clinical parameters to guide comprehensive patient management.
by Michael Boeckh, Hu Xie, Terry Stevens-Ayers, Linda Sircy, Danniel Zamora, Jason D Goldman, Christopher W Woods, Renee D Stapleton, Gordon Rubenfeld, Andre Kalil, Keith R Jerome, Sayan Dasgupta, Ajit P Limaye
